Targeting Oncogenic RAS Protein

Abstract excerpt

The authors examine the science behind the induction of objective responses in patients with NSCLC who received adagrasib, an inhibitor of a mutant version of KRAS, which was previously thought to be “undruggable.”

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell death mechanisms and regulation
• Share to Chronic Lymphocytic Leukemia Research
• Share to DNA Repair Mechanisms